Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03886987 · ClinicalTrials.gov registry record · NA
Skin Sensitization Test (Modified Draize-95 Test)
A NA study of Skin Sensitisation, sponsored by Central Medicare Sdn. Bhd..
- Completed
- Registry status
- NA
- Development phase
- 245
- Enrollment target
- 1
- Study location
NCT03886987: Completed NA study of Skin Sensitisation, sponsored by Central Medicare Sdn. Bhd..
NCT03886987 is a NA study of Skin Sensitisation that has completed, run by Central Medicare Sdn. Bhd.. The registered enrollment target is 245 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03886987, a NA study of Skin Sensitisation, has completed, sponsored by Central Medicare Sdn. Bhd..
- COMPLETED
- Registry status
- NA
- Development phase
- 245 participants
- Enrollment target
- 1
- Study location
Study Summary
Skin Sensitization Test (Modified Draize-95 Test) to Support a Low Dermatitis Potential Claim for a Blue Non Sterile Powder Free Nitrile Examination Gloves. This study is a RIPT (Repeat Insult Patch Test) to evaluate whether residual chemical additives at the level that may induce Type IV allergy in the nonsensitized general user population are present in a finished Blue Non Sterile Powder Free Nitrile Examination Glove.
Primary Outcome
Basic Score and Description: 0 - No visible reaction. 0.5 - Doubtful or negligible erythema reaction. 1.0 - Mild or just perceptible macular erythema reaction in a speckled/follicular, patchy or confluent pattern (slight pinking). 2.0 - Moderate erythema reaction in a confluent pattern (definite redness). 3.0 - Strong or brisk erythema reaction that may spread beyond the test site. If a subject develops a positive reaction (a score value of 1.5) to the test material or shows signs of irritati
Conditions Studied
Interventions
- DEVICE Blue Non Sterile Powder Free Nitrile Examination Gloves
Study Locations (1)
New Jersey
- Consumer Product Testing Company, Inc. - Fairfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2018-06-08 |
| Phase | NA |
What the finished NCT03886987 record still lists
NCT03886987 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Skin Sensitisation appearing as the primary indexed condition, and to 1 intervention - of which Blue Non Sterile Powder Free Nitrile Examination Gloves is the first listed.
NCT03886987 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT03886987 about?
NCT03886987 is a clinical study titled "Skin Sensitization Test (Modified Draize-95 Test)". Skin Sensitization Test (Modified Draize-95 Test) to Support a Low Dermatitis Potential Claim for a Blue Non Sterile Powder Free Nitrile Examination Gloves. This study is a RIPT (Repeat Insult Patch Test) to evaluate whether residual chemical additives at the level that may induce Type IV allergy in...
What is the current status of trial NCT03886987?
This trial is currently completed. It is a NA study. The enrollment target is 245 participants. The study started on 2018-04-02. Estimated completion is 2018-06-08.
What conditions does trial NCT03886987 study?
This clinical trial studies the following conditions: Skin Sensitisation.
What interventions are being tested in trial NCT03886987?
The interventions under investigation include: Blue Non Sterile Powder Free Nitrile Examination Gloves (DEVICE).
Who is sponsoring clinical trial NCT03886987?
This trial is sponsored by Central Medicare Sdn. Bhd., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03886987 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03886987's enrollment target sits among peer trials
245 436th of 2000 higher than 1,563 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI